Zacks: Brokerages Anticipate Collegium Pharmaceutical Inc (COLL) to Post -$0.11 EPS

Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to post earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.06). Collegium Pharmaceutical reported earnings of ($0.45) per share in the same quarter last year, which would indicate a positive year over year growth rate of 75.6%. The business is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.49). For the next financial year, analysts forecast that the business will post earnings of $0.60 per share, with EPS estimates ranging from $0.00 to $1.20. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.02. The firm had revenue of $73.10 million for the quarter, compared to the consensus estimate of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The company’s revenue was up 1930.6% compared to the same quarter last year.

Several analysts have weighed in on COLL shares. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Cantor Fitzgerald cut their target price on Collegium Pharmaceutical from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, August 9th. Janney Montgomery Scott set a $27.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Monday, August 6th. Piper Jaffray Companies set a $34.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, July 11th. Finally, BidaskClub downgraded Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $31.71.

Institutional investors and hedge funds have recently bought and sold shares of the company. Atria Investments LLC bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth $201,000. Cubist Systematic Strategies LLC bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth $213,000. EagleClaw Capital Managment LLC bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $220,000. Stifel Financial Corp bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $224,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth $260,000. 93.57% of the stock is currently owned by institutional investors.

Shares of Collegium Pharmaceutical stock opened at $14.74 on Friday. The company has a debt-to-equity ratio of 3.94, a quick ratio of 0.78 and a current ratio of 0.82. The firm has a market cap of $492.35 million, a price-to-earnings ratio of -5.97 and a beta of 0.39. Collegium Pharmaceutical has a 1-year low of $9.01 and a 1-year high of $29.90.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Article: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply